Oct 20, 2025 07:42AM
Oct 20, 2025 07:40AM
Oct 20, 2025 07:40AM
Aug 13, 2025 08:27AM
Aug 13, 2025 07:30AM
Jul 29, 2025 06:35AM
Jul 28, 2025 07:33AM Adaptimmune to sell cell therapy assets to US WorldMeds for $55 million
Jul 28, 2025 07:30AM
Jun 25, 2025 04:06PM
May 13, 2025 05:47PM
May 13, 2025 07:30AM
May 7, 2025 12:00PM
Apr 1, 2025 06:47AM
Mar 26, 2025 06:57AM Adaptimmune Therapeutics plc (ADAP) PT Lowered to $1.75 at Guggenheim
Mar 21, 2025 06:57AM
Mar 20, 2025 11:30AM
Mar 20, 2025 07:00AM
Mar 12, 2025 04:54PM
Jan 30, 2025 04:00PM
Jan 13, 2025 08:04AM
Jan 13, 2025 08:00AM Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
Dec 19, 2024 07:30AM
Dec 2, 2024 04:00PM
Nov 27, 2024 06:34AM
Nov 14, 2024 06:59AM
Nov 13, 2024 09:02PM
Nov 13, 2024 04:05PM
Nov 13, 2024 09:03AM Adaptimmune Therapeutics (ADAP) Reports Lete-cel Achieved Primary Endpoint in Pivotal Trial
Nov 13, 2024 09:00AM
Nov 5, 2024 09:19AM
Oct 31, 2024 05:20PM
Aug 28, 2024 08:00AM
Aug 12, 2024 07:11AM
Aug 12, 2024 07:00AM
Aug 5, 2024 08:00AM Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024
Aug 1, 2024 08:27PM
Jul 19, 2024 01:41PM

353,174 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All